From Wikipedia, the free encyclopedia
Jump to: navigation, search
Lirequinil structure.png
Systematic (IUPAC) name
CAS Number 143943-73-1 YesY
ATC code none
PubChem CID 3045375
ChemSpider 2308119 N
Chemical data
Formula C26H25ClN2O3
Molar mass 448.941 g/mol
 NYesY (what is this?)  (verify)

Lirequinil (Ro41-3696) is a nonbenzodiazepine hypnotic drug which binds to benzodiazepine sites on the GABAA receptor. In human clinical trials, lirequinil was found to have similar efficacy to zolpidem, with less side effects such as clumsiness and memory impairment. However it was also much slower acting than zolpidem, with peak plasma concentrations not reached until 2.5 hours after oral administration, and its O-desethyl metabolite Ro41-3290 is also active with a half-life of 8 hours.[1][2][3][4] This meant that while effective as a hypnotic, lirequinil failed to prove superior to zolpidem due to producing more next-day sedation, and it has not been adopted for clinical use. It was developed by a team at Hoffmann-La Roche in the 1990s.[5]

Active metabolite Ro41-3290


  1. ^ Dingemanse J, Bury M, Roncari G, Zell M, Gieschke R, Gaillard AW, Odink J, van Brummelen P (August 1995). "Pharmacokinetics and pharmacodynamics of Ro 41-3696, a novel nonbenzodiazepine hypnotic". Journal of Clinical Pharmacology. 35 (8): 821–9. doi:10.1002/j.1552-4604.1995.tb04126.x. PMID 8522640. 
  2. ^ Dingemanse J, Bury M, Bock J, Joubert P (November 1995). "Comparative pharmacodynamics of Ro 41-3696, a new hypnotic, and zolpidem after night-time administration to healthy subjects". Psychopharmacology. 122 (2): 169–74. doi:10.1007/BF02246091. PMID 8848532. 
  3. ^ Dingemanse J, Bury M, Hussain Y, van Giersbergen P (December 2000). "Comparative tolerability, pharmacodynamics, and pharmacokinetics of a metabolite of a quinolizinone hypnotic and zolpidem in healthy subjects". Drug Metabolism and Disposition: the Biological Fate of Chemicals. 28 (12): 1411–6. PMID 11095577. 
  4. ^ Dingemanse J, Pedrazzetti E, van Giersbergen PL (2001). "Multiple-dose tolerability, pharmacodynamics, and pharmacokinetics of the quinolizinone hypnotic Ro 41-3696 in elderly subjects". Clinical Neuropharmacology. 24 (2): 82–90. doi:10.1097/00002826-200103000-00003. PMID 11307042. 
  5. ^ US Patent 5561233 Process for the preparation of an intermediate of a benzo[a]quinolizinone derivative